PDF(Pubmed)
Abstract：
Background: Respiratory papillomatosis is one of the common benign lesions of the airway that is often difficult to treat and carries significant morbidity. Bevacizumab is a monoclonal antibody that acts upon vascular endothelial growth factor receptor and is known to have an effect in respiratory papillomatosis. This study aims to systematically review the literature on efficacy of intralesional Bevacizumab in juvenile onset respiratory papillomatosis. Materials and methods. A systematic search of literature in various databases was conducted. The search was restricted to the English language, however, no restrictions were made regarding the date of publication keeping December 31st, 2020 as the last date of publication. We strictly complied with the PRISMA guidelines. Results. Of 145 articles analyzed, only 3 were selected as eligible and a total of twenty-one cases were evaluated. There was improvement in anatomic Derkay score after initiating intralesional Bevacizumb with reduction in the number of surgeries. Where reported, voice related functional outcomes also were also improved. No adverse effect related to the drug was reported. Conclusion: Intralesional Bevacizumab can be a promising efficacious, and safe adjuvant in the management of JORRP. Well-designed studies are further required in the future to prove its efficacy and safety over other adjuvants available.
摘要：
背景：呼吸道乳头状瘤是气道常见的良性病变之一，通常难以治疗且发病率高。贝伐单抗是一种作用于血管内皮生长因子受体的单克隆抗体，已知对呼吸道乳头状瘤病具有作用。本研究旨在系统回顾关于贝伐单抗在青少年性呼吸道乳头状瘤病中的疗效的文献。材料和方法。对各种数据库中的文献进行了系统的检索。搜索仅限于英语，然而,12月31日的出版日期没有限制，2020年为最后发布日期。我们严格遵守PRISMA准则。结果。在分析的145篇文章中，仅3例入选合格,共评估21例.随着手术次数的减少，开始病灶内Bevacizumb后，解剖Derkay评分有所改善。据报道，与语音相关的功能结果也得到了改善.没有报告与药物相关的不良反应。结论：皮损内贝伐单抗可能是一种有前途的有效药物，和JORRP管理中的安全佐剂。未来还需要精心设计的研究来证明其相对于其他可用佐剂的功效和安全性。
